ID: MRFR/LS/4389-HCR | 100 Pages | Author: Rahul Gotadki | March 2024
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Recombinant DNA Technology Market, by Product
6.1 Introduction
6.2 Medical
6.2.1 Market Estimates & Forecast, 2020-2027
6.2.2 Therapeutic Agent
6.2.2.1 Market Estimates & Forecast, 2020-2027
6.2.3 Human Protein
6.2.3.1 Market Estimates & Forecast, 2020-2027
6.2.4 Vaccine
6.2.4.1 Market Estimates & Forecast, 2020-2027
6.3 Non-Medical
6.3.1 Market Estimates & Forecast, 2020-2027
6.3.2 Biotech Crops
6.3.2.1 Market Estimates & Forecast, 2020-2027
6.3.3 Specialty Chemicals
6.3.3.1 Market Estimates & Forecast, 2020-2027
6.3.4 Others
6.3.4.1 Market Estimates & Forecast, 2020-2027
6.4 Others
Chapter 7. Global Recombinant DNA Technology Market, by Component
7.1 Introduction
7.2 Expression System
7.2.1 Market Estimates & Forecast, 2020-2027
7.2.2 Mammalian
7.2.2.1 Market Estimates & Forecast, 2020-2027
7.2.3 Bacteria
7.2.3.1 Market Estimates & Forecast, 2020-2027
7.2.4 Yeast
7.2.4.1 Market Estimates & Forecast, 2020-2027
7.2.4 BaculovirU.S./Insect
7.2.4.1 Market Estimates & Forecast, 2020-2027
7.2.5 Others
7.2.5.1 Market Estimates & Forecast, 2020-2027
7.3 Cloning Vector
7.3.1 Market Estimates & Forecast, 2020-2027
7.3.2 Plasmid
7.3.2.1 Market Estimates & Forecast, 2020-2027
7.3.3 Phage
7.3.3.1 Market Estimates & Forecast, 2020-2027
7.3.4 Cosmid
7.3.4.1 Market Estimates & Forecast, 2020-2027
7.3.5 Bacterial Artificial Chromosome (BAC)
7.3.5.1 Market Estimates & Forecast, 2020-2027
7.3.6 Yeast Artificial Chromosome (YAC)
7.3.6.1 Market Estimates & Forecast, 2020-2027
7.3.7 Human Artificial Chromosome (HAC).
7.3.7.1 Market Estimates & Forecast, 2020-2027
7.4 Others
Chapter 8. Global Recombinant DNA Technology Market, by Application
8.1 Introduction
8.2 Food & Agriculture
8.2.1 Market Estimates & Forecast, 2020-2027
8.3 Health & Disease
8.3.1 Market Estimates & Forecast, 2020-2027
8.4 Environment
8.4.1 Market Estimates & Forecast, 2020-2027
8.5 Others
Chapter 9. Global Recombinant DNA Technology Market, by End-U.S.er
9.1 Introduction
9.2 Biotechnology Companies
9.2.1 Market Estimates & Forecast, 2020-2027
9.3 Academic & Government Research Institutes
9.3.1 Market Estimates & Forecast, 2020-2027
9.4 Pharmaceuticals
9.4.1 Market Estimates & Forecast, 2020-2027
9.5 Others
Chapter .8 Global Recombinant DNA Technology Market, by Region
8.1 Introduction
8.2 Americas
8.2.1 North America
8.2.1.1 U.S.
8.2.1.1 Canada
8.2.2 South America
8.3 Europe
8.3.1 Western Europe
8.3.1.1 Germany
8.3.1.2 France
8.3.1.3 Italy
8.3.1.4 Spain
8.3.1.5 U.K.
8.3.1.6 Rest of Western Europe
8.3.2 Eastern Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 Republic of Korea
8.4.6 Rest of Asia Pacific
8.5 The Middle East & Africa
8.5.1 United Arab Emirates
8.5.2 Saudi Arabia
8.5.3 Oman
8.5.4 Kuwait
8.5.5 Qatar
8.5.6 Rest of the Middle East & Africa
Chapter 9 Company Landscape
9.1 Introduction
9.2 Market Share Analysis
9.3 Key Development & Strategies
9.3.1 Key Developments
Chapter 10 Company Profiles
10.1 F. Hoffmann-La Roche Ltd
10.1.1 Company Overview
10.1.2 Product Overview
10.1.3 Financials
10.1.4 SWOT Analysis
10.2 Profacgen
10.2.1 Company Overview
10.2.2 Product Overview
10.2.3 Financial Overview
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Amgen Inc.
10.3.1 Company Overview
10.3.2 Product Overview
10.3.3 Financial Overview
10.3.4 Key Development
10.3.5 SWOT Analysis
10.4 Novartis AG
10.4.1 Company Overview
10.4.2 Product/Business Segment Overview
10.4.3 Financial Overview
10.4.4 Key Development
10.4.5 SWOT Analysis
10.5 Genscript Biotech
10.5.1 Company Overview
10.5.2 Product Overview
10.5.3 Financial overview
10.5.4 Key Developments
10.6 Pfizer Inc.
10.6.1 Company Overview
10.6.2 Product Overview
10.6.3 Financial Overview
10.6.4 Key Developments
10.7 Novo Nordisk A/S
10.7.1 Overview
10.7.2 Product Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 Eli Lilly and Company
10.8.1 Company Overview
10.8.2 Product/Business Segment Overview
10.8.3 Financial Overview
10.8.4 Key Development
10.8.5 SWOT Analysis
10.9 Sanofi S.A.
10.9.1 Company Overview
10.9.2 Product Overview
10.9.3 Financial overview
10.9.4 Key Developments
10.10 Merck & Co., Inc.
10.10.1 Company Overview
10.10.2 Product Overview
10.10.3 Financial overview
10.10.4 Key Developments
10.11 Biogen Inc.
10.11.1 Company Overview
10.11.2 Product Overview
10.11.3 Financial overview
10.11.4 Key Developments
10.12 Others
Chapter 17 MRFR Conclusion
11.1 Key Findings
11.1.1 From CEO’s View Point
11.1.2 Unmet Needs of the Market
11.2 Key Companies to Watch
11.3 Prediction of the Pharmaceutical Industry
Chapter 12 Appendix
LIST OF TABLES
Table 1 Recombinant DNA technology Industry Synopsis, 2020-2027
Table 2 Recombinant DNA Technology Market Estimates & Forecast, 2020-2027, (USD Million)
Table 3 Recombinant DNA Technology Market, by Region, 2020-2027, (USD Million)
Table 4 Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 5 Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 6 Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 7 Recombinant DNA Technology Market, by End-U.S.er, 2020-2027, (USD Million)
Table 8 North America Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 9 North America Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 10 North America Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 11 North America Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)
Table 12 U.S. Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 13 U.S. Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 14 U.S. Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 15 U.S. Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)
Table 16 Canada Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 17 Canada Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 18 Canada Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 19 Canada Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)
Table 20 South America Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 21 South America Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 22 South America Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 23 South America Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)
Table 24 Europe Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 25 Europe Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 26 Europe Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 27 Europe Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)
Table 28 Western Europe Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 29 Western Europe Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 30 Western Europe Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 31 Western Europe Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)
Table 32 Eastern Europe Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 33 Eastern Europe Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 34 Eastern Europe Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 35 Eastern Europe Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)
Table 36 Asia Pacific Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 37 Asia Pacific Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 38 Asia Pacific Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 39 Asia Pacific Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)
Table 40 The Middle East & Africa Recombinant DNA Technology Market, by Product, 2020-2027, (USD Million)
Table 41 The Middle East & Africa Recombinant DNA Technology Market, by Component, 2020-2027, (USD Million)
Table 42 The Middle East & Africa Recombinant DNA Technology Market, by Application, 2020-2027, (USD Million)
Table 43 The Middle East & Africa Recombinant DNA Technology Market, by End-User, 2020-2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation of the Recombinant DNA Technology Market
Figure 3 Segmentation Market Dynamics for the Recombinant DNA Technology Market
Figure 4 Global Recombinant DNA Technology Market Share, by Product 2020
Figure 5 Global Recombinant DNA Technology Market Share, by Component 2020
Figure 6 Global Recombinant DNA Technology Market Share, by Application 2020
Figure 7 Global Recombinant DNA Technology Market Share, by End-User2020
Figure 8 Global Recombinant DNA Technology Market Share, by Region, 2020
Figure 9 Americas Recombinant DNA Technology Market Share, by Country, 2020
Figure 10 Europe Recombinant DNA Technology Market Share, by Country, 2020
Figure 11 Asia Pacific Recombinant DNA Technology Market Share, by Country, 2020
Figure 12 Middle East & Africa Recombinant DNA Technology Market Share, by Country, 2020
Figure 13 Global Recombinant DNA Technology Market: Company Share Analysis, 2020 (%)
Figure 14 F. Hoffmann-La Roche Ltd: Key Financials
Figure 15 F. Hoffmann-La Roche Ltd: Segmental Revenue
Figure 16 F. Hoffmann-La Roche Ltd: Geographical Revenue
Figure 17 Profacgen: Key Financials
Figure 18 Profacgen: Segmental Revenue
Figure 19 Profacgen: Geographical Revenue
Figure 20 Amgen Inc.: Key Financials
Figure 21 Amgen Inc.: Segmental Revenue
Figure 22 Amgen Inc.: Geographical Revenue
Figure 23 Novartis AG: Key Financials
Figure 24 Novartis AG: Segmental Revenue
Figure 25 Novartis AG: Geographical Revenue
Figure 26 Genscript Biotech: Key Financials
Figure 27 Genscript Biotech: Segmental Revenue
Figure 28 Genscript Biotech: Geographical Revenue
Figure 29 Pfizer Inc.: Key Financials
Figure 30 Pfizer Inc.: Segmental Revenue
Figure 31 Pfizer Inc.: Geographical Revenue
Figure 32 Novo Nordisk A/S: Key Financials
Figure 33 Novo Nordisk A/S: Segmental Revenue
Figure 34 Novo Nordisk A/S: Geographical Revenue
Figure 35 Eli Lilly and Company: Key Financials
Figure 36 Eli Lilly and Company: Segmental Revenue
Figure 37 Eli Lilly and Company: Geographical Revenue
Market Segmentation
Recombinant DNA Technology Product Outlook (USD Billion, 2018-2032)
Medical
Non-Medical
Recombinant DNA Technology Component Outlook (USD Billion, 2018-2032)
Expression System
Cloning Vector
Recombinant DNA Technology Application Outlook (USD Billion, 2018-2032)
Food & Agriculture
Health & Disease
Recombinant DNA Technology End User Outlook (USD Billion, 2018-2032)
Biotechnology Companies
Pharmaceuticals
Recombinant DNA Technology Regional Outlook (USD Billion, 2018-2032)
North America Outlook (USD Billion, 2018-2032)
North America Recombinant DNA Technology by Product
Medical
Non-Medical
North America Recombinant DNA Technology by Component
Expression System
Cloning Vector
North America Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
North America Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
US Outlook (USD Billion, 2018-2032)
US Recombinant DNA Technology by Product
Medical
Non-Medical
US Recombinant DNA Technology by Component
Expression System
Cloning Vector
US Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
US Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
CANADA Outlook (USD Billion, 2018-2032)
CANADA Recombinant DNA Technology by Product
Medical
Non-Medical
CANADA Recombinant DNA Technology by Component
Expression System
Cloning Vector
CANADA Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
CANADA Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
Europe Outlook (USD Billion, 2018-2032)
Europe Recombinant DNA Technology by Product
Medical
Non-Medical
Europe Recombinant DNA Technology by Component
Expression System
Cloning Vector
Europe Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
Europe Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
Germany Outlook (USD Billion, 2018-2032)
Germany Recombinant DNA Technology by Product
Medical
Non-Medical
Germany Recombinant DNA Technology by Component
Expression System
Cloning Vector
Germany Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
Germany Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
France Outlook (USD Billion, 2018-2032)
France Recombinant DNA Technology by Product
Medical
Non-Medical
France Recombinant DNA Technology by Component
Expression System
Cloning Vector
France Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
France Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
UK Outlook (USD Billion, 2018-2032)
UK Recombinant DNA Technology by Product
Medical
Non-Medical
UK Recombinant DNA Technology by Component
Expression System
Cloning Vector
UK Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
UK Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
ITALY Outlook (USD Billion, 2018-2032)
ITALY Recombinant DNA Technology by Product
Medical
Non-Medical
ITALY Recombinant DNA Technology by Component
Expression System
Cloning Vector
ITALY Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
ITALY Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
SPAIN Outlook (USD Billion, 2018-2032)
Spain Recombinant DNA Technology by Product
Medical
Non-Medical
Spain Recombinant DNA Technology by Component
Expression System
Cloning Vector
Spain Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
Spain Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
Rest Of Europe Outlook (USD Billion, 2018-2032)
Rest Of Europe Recombinant DNA Technology by Product
Medical
Non-Medical
Rest Of Europe Recombinant DNA Technology by Component
Expression System
Cloning Vector
Rest Of Europe Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
Rest Of Europe Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
Asia-Pacific Outlook (USD Billion, 2018-2032)
Asia-Pacific Recombinant DNA Technology by Product
Medical
Non-Medical
Asia-Pacific Recombinant DNA Technology by Component
Expression System
Cloning Vector
Asia-Pacific Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
Asia-Pacific Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
China Outlook (USD Billion, 2018-2032)
China Recombinant DNA Technology by Product
Medical
Non-Medical
China Recombinant DNA Technology by Component
Expression System
Cloning Vector
China Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
China Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
Japan Outlook (USD Billion, 2018-2032)
Japan Recombinant DNA Technology by Product
Medical
Non-Medical
Japan Recombinant DNA Technology by Component
Expression System
Cloning Vector
Japan Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
Japan Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
India Outlook (USD Billion, 2018-2032)
India Recombinant DNA Technology by Product
Medical
Non-Medical
India Recombinant DNA Technology by Component
Expression System
Cloning Vector
India Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
India Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
Australia Outlook (USD Billion, 2018-2032)
Australia Recombinant DNA Technology by Product
Medical
Non-Medical
Australia Recombinant DNA Technology by Component
Expression System
Cloning Vector
Australia Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
Australia Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)
Rest of Asia-Pacific Recombinant DNA Technology by Product
Medical
Non-Medical
Rest of Asia-Pacific Recombinant DNA Technology by Component
Expression System
Cloning Vector
Rest of Asia-Pacific Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
Rest of Asia-Pacific Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
Rest of the World Outlook (USD Billion, 2018-2032)
Rest of the World Recombinant DNA Technology by Product
Medical
Non-Medical
Rest of the World Recombinant DNA Technology by Component
Expression System
Cloning Vector
Rest of the World Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
Rest of the World Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
Middle East Outlook (USD Billion, 2018-2032)
Middle East Recombinant DNA Technology by Product
Medical
Non-Medical
Middle East Recombinant DNA Technology by Component
Expression System
Cloning Vector
Middle East Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
Middle East Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
Africa Outlook (USD Billion, 2018-2032)
Africa Recombinant DNA Technology by Product
Medical
Non-Medical
Africa Recombinant DNA Technology by Component
Expression System
Cloning Vector
Africa Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
Africa Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals
Latin America Outlook (USD Billion, 2018-2032)
Latin America Recombinant DNA Technology by Product
Medical
Non-Medical
Latin America Recombinant DNA Technology by Component
Expression System
Cloning Vector
Latin America Recombinant DNA Technology by Application
Food & Agriculture
Health & Disease
Latin America Recombinant DNA Technology by End User
Biotechnology Companies
Pharmaceuticals